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Background: The purpose of this study was to evaluate the effects of topical nipradilol 
monotherapy for 5 years on intraocular pressure, visual field performance, and optic disk 
topography.
Methods: Thirty patients with normal tension glaucoma were monitored for intraocular pressure 
every 1–3 months. A Humphrey visual field test and measurement of optic disk configuration 
using the Heidelberg retina tomograph II was done after every year of treatment and the results 
compared with those before treatment. Visual field performance was also evaluated by trend 
and event analysis.
Results: The mean intraocular pressure ± standard deviation after 3 years of nipradilol treat-
ment (14.1 ± 2.0 mmHg) and after 5 years of nipradilol treatment (13.7 ± 2.1 mmHg) was sig-
nificantly lower than that before treatment (17.0 ± 1.8 mmHg, P , 0.0001). Heidelberg retina 
tomograph II parameters, such as mean cup depth and height variation contour after treatment, 
were significantly increased compared with those before treatment. Visual field performance 
worsened in eight eyes by trend analysis and eight eyes by event analysis.
Conclusion: Nipradilol monotherapy was effective in reducing intraocular pressure over at 
least 5 years without worsening of optic disk topography. Furthermore, mean cup depth and 
height variation contour were also significantly improved. However, visual field performance 
worsened in 16.0% of patients with normal tension glaucoma.
Keywords: nipradilol, intraocular pressure, Heidelberg retina tomograph II, trend analysis, 
event analysis
Introduction
The only medical treatment for patients with normal tension glaucoma that shows 
evidence of preserving the visual fields is reduction of intraocular pressure (IOP).1,2 
Thus, IOP reduction with eye drops is generally the first-line treatment. For evaluation 
of the response to glaucoma therapy, IOP measurement and detection of visual field 
defects by visual field tests are usually conducted. Because normal tension glaucoma 
is a chronic progressive condition that is generally accompanied by slowly progres-
sive visual field loss, judging the progress of this condition is difficult and long-term 
observation of the patient is needed. The following methods are used to evaluate the 
progression of visual field disorders: clinical evaluation, various evaluation criteria,3 
disease stage classifications,4 linear regression (trend) analysis,5 and event analysis.6 
There are various criteria for evaluating the progression of visual field loss, and 
results may differ depending on the criteria used. Changes in optic disk topography 
may precede the progression of visual field loss, but few studies have investigated Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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changes in the optic disk over a long period in patients with 
glaucoma receiving drugs for IOP reduction and operation.7–10 
Monitoring longitudinal changes of the optic disk may be 
useful during the treatment of glaucoma. Recent technical 
advances have led to the availability of methods such as scan-
ning laser ophthalmoscopy, optical coherence tomography, 
or scanning laser polarimetry, which are expected to be used 
more in the future.
We encounter some patients who have sufficiently low IOP 
and who still have an IOP-lowering efficiency of 20%–30% 
from baseline, but still suffer from progressive visual field 
loss. Ocular circulatory dysfunction and apoptosis of retinal 
ganglion cells may be involved rather than IOP in those 
patients. Nipradilol is an antiglaucoma ophthalmic agent with 
nonselective β-receptor and selective α1-receptor blocking 
properties.11–14 IOP decreases because of a decline in aque-
ous humor production by the β interceptor and accelerated 
aqueous outflow by the α interceptor. Nipradilol was reported 
to have hypotensive effects in normal tension glaucoma.8,15,16 
In addition to reducing IOP, other effects of nipradilol are 
reported to include improvement of ocular blood flow via 
release of nitric oxide that causes vasodilation17,18 and neuro-
protection via inhibition of apoptosis of the retinal ganglion 
cells.19,20 These circulatory and neuroprotective effects on 
the optic disk are expected to contribute to maintaining the 
visual fields.
The purpose of the present study was to evaluate changes 
in IOP, visual fields, and optic disk topography during treat-
ment with nipradilol for normal tension glaucoma over an 
extended observation period of 5 years. This was an exten-
sion of our previous study of 3 years of treatment with 
nipradilol.8
Patients and methods
The study included 30 Japanese patients (50 eyes, 13 men 
and 17 women) with normal tension glaucoma who started 
treatment with nipradilol eye drops as monotherapy for 
glaucoma at Inouye Eye Hospital between April 2003 and 
March 2004. All patients met the enrollment criteria, did not 
meet any of the exclusion criteria, and were available for 
observation over 5 years. Their mean age was 52.4 ± 12.5 
(range 29–76) years. Four patients had hypertension, two 
had diabetes, two had gout, one had hypothyroidism, and 
one had a sleep disorder, and all were on oral treatment for 
these conditions. This study was performed in accordance 
with the Declaration of Helsinki and was approved by our 
ethical committee. All patients received an explanation of 
the procedures and possible risks of the study, and gave their 
written informed consent. The criteria for diagnosing normal 
tension glaucoma were: IOP # 21 mmHg when measured 
several times to evaluate circadian variation; specific changes 
for glaucoma in the optic disk and the retinal nerve fiber 
layer (thinning of the optic disk margin and defects of the 
nerve fiber layer); identification of visual field defects with 
a high reliability and reproducibility, which were consistent 
with glaucomatous morphologic changes; absence of other 
eye diseases or congenital abnormalities that could lead to 
visual field changes; and normal open angle in both eyes 
on gonioscopy. The exclusion criteria were corrected visual 
acuity # 0.5, previous intraocular surgery, laser therapy, or 
systemic steroid therapy, otolaryngological or neurosurgi-
cal abnormalities, and diabetes mellitus. If one eye met the 
diagnostic criteria, the other eye was studied. If both eyes 
met the diagnostic criteria, then both eyes were studied. 
Adherence to eye drop treatment was confirmed verbally 
at every assessment visit. None of the patients underwent 
cataract surgery or any kind of intraocular surgery during 
the 5-year study period.
The Humphrey 30-2 SITA standard program was used 
for determination of the visual fields, with the mean devia-
tion and pattern standard deviation being used as indices of 
visual field impairment during treatment. Patients in whom 
false-positive results, false-negative results, or poor fixation 
accounted for 20% or more of the assessments were excluded 
from evaluation of visual fields.
After starting treatment with nipradilol (Hypadil Kowa 
Ophthalmic Solution 0.25%, Kowa, Nagoya, Japan) twice 
a day, IOP measurement was performed using a Gold-
mann applanation tonometer at the same time of day on 
each patient every 1–3 months. Visual field assessment 
(Humphrey 30-2 SITA standard program) and measure-
ment of the optic disk were performed every 6 months. 
Optic nerve head topography parameters were measured 
using a Heidelberg retina tomograph II (HRT-II, v 3.1.2.4; 
Heidelberg Engineering GmbH, Heidelberg, Germany). 
HRT II uses a diode laser (670 nm wavelength) to scan the 
retinal surface sequentially in the horizontal and vertical 
directions on multiple focal planes. By using confocal scan-
ning principles, a three-dimensional topographic image is 
acquired in consecutive focal planes. The topographic image 
determined from the acquired three-dimensional image 
consists of 384 × 384 (147,456) pixels, each of which is 
a measurement of the surface height of the retina and the 
optic nerve head at the corresponding location. Three 
  topographic images were obtained, combined, and auto-
matically aligned to create a single mean topographic Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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image for   analysis. Image   acquisition was performed by 
three skilled   operators, and contour lines were drawn and 
determined by an   ophthalmologist (KI). If the standard 
deviation of the mean topographic image at each assessment 
was .30 µm, the data for the patient were excluded from 
evaluation of morphology of the optic disk. From those 
results, 46 eyes were studied. The optic disk parameters 
included the cup/disk area ratio, rim volume (mm3), mean 
cup depth (mm), height variation contour (mm), and mean 
retinal nerve fiber layer thickness (mm).
The IOP value obtained before administration of nip-
radilol was compared with those obtained every 3 months 
after the start of treatment by repeated-measures analysis 
of variance and a multiple comparison test (Bonferroni/
Dunnet). The visual field parameters (mean deviation and 
pattern standard deviation) and HRT II parameters before 
administration of nipradilol were also compared with data 
obtained every year after the start of treatment using repeated-
measures analysis of variance and multiple comparisons 
(Bonferroni/Dunnet).
statistical analysis
The level of significance was defined as P , 0.05 for IOP, 
mean deviation, analysis of variance, and HRT II parameters. 
Trend analysis and event analysis were applied to evaluate 
the progression of visual field loss. For trend analysis, linear 
regression was used to judge sequential changes in mean 
deviation, with the annual change in mean deviation (dB/
year) being calculated along with its statistical significance.5 
When test results exceeded threshold levels compared with 
baseline values (measured twice at the beginning of the 
observation period), the patient was regarded as showing 
progression. For event analysis, glaucoma was defined as 
showing “possible progression” when two consecutive mea-
surements revealed a significant decrease by three or more 
points and as showing “progression” when three consecutive 
measurements revealed a significant decrease by three or 
more points.6 The time when “progression” in the present 
study was observed was defined as the time when the loss 
of visual field occurred.
Results
The mean IOP before starting treatment with nipradilol eye 
drops was 17.0 ± 1.8 mmHg (13 mmHg in one eye, 14 mmHg 
in four eyes, 15 mmHg in one eye,16 mmHg in 21 eyes, 
18 mmHg in 13 eyes, 19 mmHg in four eyes, and 20 mmHg in 
six eyes). The mean refractive power was −2.1 ± 2.8 D (−8.25 
to +2.50 D). The mean deviation at the beginning of treatment 
was −6.2 ± 6.2 dB (−25.8 to −1.41 dB) and the mean pattern 
standard deviation was 7.7 ± 4.5 dB (1.6 to 16.5 dB).
The mean IOP was 14.2 ± 1.6, 13.9 ± 1.6, 14.0 ± 2.0, 
14.1 ± 1.9, and 13.7 ± 2.1 mmHg at years 1, 2, 3, 4, and 5 
after starting nipradilol eye drops, respectively, and all of 
these values significantly decreased when compared with 
the pretreatment value (P , 0.0001, Figure 1). The mean 
IOP reduction width was 2.8 ± 1.7, 3.1 ± 1.7, 3.0 ± 2.0, 
2.9 ± 1.8, and 3.3 ± 2.0 mmHg at years 1, 2, 3, 4, and 5 
after starting nipradilol eye drops, respectively, and there 
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Figure 1 Intraocular pressure (IOP) at baseline and after treatment with nipradilol (mean ± standard deviation).
Note: **P , 0.0001, analysis of variance, Bonferroni and Dunnet multiple comparison tests.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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was a significant decrease at year 5 compared with years 
1 and 4 (P = 0.0452). The mean IOP reduction rate was 
16.0% ± 9.3%, 18.1% ± 8.6%, 17.2% ± 10.3%, 16.7% ± 9.6%, 
and 19.0% ± 10.9% at years 1, 2, 3, 4, and 5 after starting 
nipradilol eye drops, respectively, and there was a significant 
decrease at years 2 and 5 compared with year 1, and at year 
5 compared with years 1 and 4 (P = 0.0366).
The mean deviation values were −6.8 ± 6.4, −5.5 ± 5.4, 
−5.9 ± 5.9, −5.6 ± 5.4, and −5.8 ± 5.3 dB at years 1, 2, 3, 4, 
and 5 after starting nipradilol eye drops, respectively, all of 
which were without a significant decrease compared with 
the pretreatment value (P = 0.1052, Figure 2). The mean 
pattern standard deviation was 8.4 ± 4.4, 7.7 ± 4.3, 8.1 ± 4.6, 
8.2 ± 4.4, and 8.5 ± 4.5 dB at years 1, 2, 3, 4, and 5 after 
starting nipradilol eye drops, respectively, all of which were 
also without a significant decrease compared with the pre-
treatment value (P = 0.4717, Figure 2).
Eight eyes showed “progression” in visual field loss by 
trend analysis, while eight eyes were evaluated by event 
analysis (Figure 3). Seven eyes had progression in visual field 
loss according to both trend analysis and event   analysis. In 
the HRT II parameters, mean cup depth and height variation 
contour were significantly increased, but the other factors 
were not (Table 1).
Discussion
With regards to the IOP-reducing effect of nipradilol mono-
therapy for normal tension glaucoma, the absolute range of 
IOP reduction was reported to be 0.9–3.1 mmHg and the 
relative decrease of IOP was reported to be 6.4%–18.3%.8,15,16 
Yukawa et al15 administered nipradilol for 36 months to 
46 patients with a pretreatment IOP of 15.7 ± 3.2 mmHg. 
They reported that the IOP significantly decreased from 
13.7–14.7 mmHg, with the range of IOP reduction being 
1.0–2.0 mmHg and the relative decrease of IOP being 
6.4%–12.7%. Araie et al16 randomized 146 patients to receive 
nipradilol or timolol treatment and observed them for 3 years. 
In the patients treated with nipradilol, IOP showed a signifi-
cant decrease from 14.1 ± 1.7 mmHg to 13.2 ± 1.9 mmHg 
over the 3-year period. In our previous report,8 we determined 
that the IOP significantly decreased during the treatment 
period from 16.9 ± 1.7 mmHg to 13.8 ± 14.1 mmHg, with an 
absolute reduction of 2.8–3.1 mmHg and a relative decrease 
of 16.5%–18.3% by administering nipradilol for 3 years to 
31 patients. In the present study, the absolute range of IOP 
reduction was 2.9–3.3 mmHg and the relative decrease was 
17.1%–19.4%, which were similar findings to those of our 
previous study8 and better compared with other reports.15,16 
This difference may have been related to the higher 
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Figure 2 Mean deviation (MD) and pattern standard deviation (PsD) at baseline and years 1, 2, 3, 4, and 5 of treatment with nipradilol.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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  pretreatment IOP in our present study (17.0 ± 1.7 mmHg) and 
our previous study (16.9 ± 1.7 mmHg)8 than in other studies 
(15.7 ± 3.2 mmHg15 and 14.1 ± 1.7 mmHg16).
Several studies have shown a visual field-preserving effect 
of nipradilol treatment for three or more years in patients with 
normal tension glaucoma.8,15,16 Yukawa et al15 reported that 
the visual field preservation rate was 83.2% after 4 years of 
treatment. They defined a decrease by 3 dB or more of the 
mean deviation calculated from two measurements obtained 
with Humphrey perimetry as progression of visual field loss. 
In the present study, the visual field preservation rate after 
5 years was 86.7% when calculated by the same criterion. 
Araie et al16 reported that, over a 3-year administration, no 
change was observed in the mean annual progression of 
mean deviation (0.002 ± 2.248 dB/year) and a significant 
decrease was found in the mean annual progression of the 
corrected pattern standard deviation (0.322 ± 1.364 dB/year). 
Additionally, when the visual fields were classified into six 
regions, the mean annual progression of total deviation was 
significantly improved in the two upper regions from the 
center, while no change was found in the other four regions 
(upper peripheral and lower). In the present study, evalua-
tion by this method was not performed, but the mean annual 
progression of mean deviation was −0.01 ± 0.36 dB/year and 
there were no significant changes. The progression of visual 
field disorder, such as visual field preservation rate and mean 
annual progression of mean deviation, was no different in 
the present study, when compared with past reports.15,16 In 
the previous 3-year study of 31 patients, the mean annual 
progression of mean deviation was 0.09 ± 0.83 dB/year, 
which also did not show any significant changes.8 In the 
present study, trend analysis and event analysis was used 
for assessment of visual field disorder progression. Seven 
of eight eyes (trend analysis) and seven of eight eyes (event 
analysis) both showed progression, so the results of both 
analyses were similar. However, no one was conscious of 
visual field disorder in these 50 cases.
There have been a few reports about longitudinal changes 
in optic disk topography in patients with glaucoma who 
have received IOP-reducing drugs and undergone surgery 
for 3 years or longer.7–10 Tomita et al7 reported patients with 
normal tension glaucoma who were assigned to treatment 
with latanoprost or timolol for 3 years. They found that the 
cup/disk ratio of the longitudinal diameter and the marginal 
area on stereographs of the optic disk showed no significant 
difference in both groups. Kalaboukhova et al9 reported a 
change in HRT parameters with glaucoma patients treated 
with medication and/or surgery for 50 months. Based on 
analyses of optic disk photographs and high-pass resolu-
tion perimetry, eyes were classified as progressive or stable. 
In the progressive group, HRT II parameters such as cup 
shape measurement, classification index, the third moment 
in contour, cup/disk ratio, cup area, rim area, and area below 
references significantly worsened. On the other hand, in the 
stable group, no HRT II parameters had changed significantly. 
Harju et al10 reported the change of HRT II parameters in 
glaucoma patients treated with medication and/or surgery for 
6 months. Rim area and maximum cup depth had decreased 
significantly, and cup shape measure increased. Analysis of 
optic disk morphology by HRT II in the present study showed 
that all of the parameters at years 1, 2, 3, 4, and 5 after nipra-
dilol treatment did not worsen compared with pretreatment 
values, as was shown in our previous 3-year study.8 Further-
more, the mean cup depth and height variation contour were 
Event
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1 case 1 case
7 cases
Figure 3 Analysis advanced with visual field deficit (trend analysis, event analysis).
Table 1 heidelberg retina tomograph II parameters at baseline and years 1, 2, 3, 4, and 5 of treatment with nipradilol
Pretreatment 1 year 2 years 3 years 4 years 5 years P
Cup/disc area ratio 0.50 ± 0.18 0.52 ± 0.15 0.50 ± 0.20 0.51 ± 0.19 0.52 ± 0.17 0.49 ± 0.18 0.4
rim volume (mm3) 0.26 ± 0.19 0.29 ± 0.18 0.28 ± 0.21 0.30 ± 0.22 0.28 ± 0.18 0.31 ± 0.19 0.04
Mean cup depth (mm) 0.32 ± 0.10 0.32 ± 0.09 0.31 ± 0.10 0.32 ± 0.10 0.33 ± 0.09 0.32 ± 0.10 0.12
height variation contour (mm) 0.45 ± 0.16 0.49 ± 0.17 0.50 ± 0.18 0.53 ± 0.15 0.52 ± 0.16 0.54 ± 0.1 8 0.01
Mean rnFL thickness (mm) 0.21 ± 0.13 0.24 ± 0.11 0.23 ± 0.14 0.25 ± 0.12 0.24 ± 0.12 0.24 ± 0.14 0.05
Note: *P , 0.05, analysis of variance, Bonferroni and Dunnet multiple comparison tests.
Abbreviation: RNFL, retinal nerve fiber layer.Clinical Ophthalmology
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  significantly improved. These changes in the optic nerve head 
are the result of nipradilol treatment. There is a hypothesis 
that if the morphology of the cup improves first, the rim and 
nerve fiber layer defect are likely to improve next. In previous 
reports8–10 and in the present study, various HRT II parameters 
changed (worsened or improved) significantly.
Only one patient dropped out of the study between the pre-
vious 3-year evaluation (31 patients)8 and the present 5-year 
evaluation (30 patients). This patient discontinued treatment 
after 4 years because of inability to meet the study schedule. 
Thus, patients who have used the eye drops for 3 years or 
longer are unlikely to develop new adverse effects.
We assessed the effect of nipradilol for 5 years on IOP, 
visual field, and optic nerve head. However, because there 
was no control group, it is not possible to say that the changes 
in IOP, visual field, and optic nerve head form were attribut-
able to nipradilol.
In conclusion, after treatment with nipradilol eye drops 
of 50 eyes in 30 patients with normal tension glaucoma for 
5 years, there was a significant decrease of IOP, no worsened 
optic disk topography parameters, and progressive visual 
field loss in 16.0% of patients.
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